glp 1 next generation Next-Generation Anti-Obesity Medicines GLP-1 Orals and Multi-Agonists: Advancing

[4] These gastrointestinal symptoms are often mild to moderate in severity and tend to diminish over time as the body adjusts to the medication

doi: 10.1002/mnfr.200700048 113 BowkerNHansfordRBurgessSFoleyCNAuyeungVPWErzurumluogluAMet al

Reduction of atherosclerosis requires long-term treatment [53], hence longer trials are better suited to show a reduction in risk of myocardial infarction or other atherosclerotic complications of diabetes

We would always recommend tapering the medication really gradually in order to avoid rebound effects

Deficient counterregulation: A possible risk factor for excessive fetal growth in IDDM pregnancies